I have taken it for months with no problems. Doesn't that tell me something?

It tells you about the last few months in one person. Immunogenicity and organ-level effects are not sensations, which is why they are found in monitored studies rather than noticed by users. There is also no assayed concentration behind a grey-market vial, so you do not know what quantity produced the experience you are describing.

AstraZeneca is running a trial on this target. Should I wait for the result?

It will not answer the question you are asking. AZD4248 is a different molecule at phase 1, which is a safety and tolerability stage rather than a weight-loss test. A result there would say something about NNMT inhibition as a direction and nothing about 5-Amino-1MQ.

Which compounds in this category do have human evidence?

Sorted by that exact question, most of them have none. The overview page separates the approved medicines from the pipeline compounds and the research chemicals, with the trial figures attached where they exist. Anything with no line in that column is being sold on mechanism.

Research-Chemical Peptides and the Grey Market

What this page establishes

A targeted PubMed search returns no human clinical trial of 5-Amino-1MQ: zero human safety data and zero human efficacy data.
5-Amino-1MQ is not FDA-approved and is sold as an unregulated research chemical.
FDA's stated concerns for the peptide Category 2 list were immunogenicity risk, peptide-related impurities and insufficient safety data, which are the same quality concerns that apply to grey-market supply.
FDA has found compounded GLP-1 products containing salt forms not equivalent to the approved active ingredient, demonstrating that non-standard supply chains do produce mislabelled actives.

Quick answers

I have taken it for months with no problems. Doesn't that tell me something?
It tells you about the last few months in one person. Immunogenicity and organ-level effects are not sensations, which is why they are found in monitored studies rather than noticed by users.
Read the full answer
There is also no assayed concentration behind a grey-market vial, so you do not know what quantity produced the experience you are describing.
AstraZeneca is running a trial on this target. Should I wait for the result?
It will not answer the question you are asking. AZD4248 is a different molecule at phase 1, which is a safety and tolerability stage rather than a weight-loss test.
Read the full answer
A result there would say something about NNMT inhibition as a direction and nothing about 5-Amino-1MQ.
Which compounds in this category do have human evidence?
Sorted by that exact question, most of them have none. The overview page separates the approved medicines from the pipeline compounds and the research chemicals, with the trial figures attached where they exist.
Read the full answer
Anything with no line in that column is being sold on mechanism.

5-Amino-1MQ has a coherent mechanism, genuine preclinical results, active marketing and not one published human trial of any kind. That makes it the best available case for understanding what a missing human dataset means, because there is nothing else wrong with the story. The science is not fake. It stops before the point where it would tell you anything about people. From there the same reasoning applies to the rest of the grey market.

What a research chemical is in this market

A research chemical is a substance sold with a label stating it is not for human consumption. The label is a legal position taken by the seller, which shifts responsibility to the buyer. It is not an inspection, a certification or a statement about what is in the vial. No agency has confirmed identity, assayed concentration, tested sterility or reviewed manufacturing. The absence is the business model, not an oversight.

5-Amino-1MQ: the mechanism story

5-Amino-1MQ inhibits nicotinamide N-methyltransferase, an enzyme called NNMT that is highly expressed in fat tissue. Inhibiting it in adipose tissue raised intracellular NAD+ and SAM, suppressed lipogenesis, and reduced body weight and white-fat mass in diet-induced obese mice. Diet-induced obese rats showed about 6% body-weight reduction over 11 days.

This is a real mechanism with real animal data behind it, and it is worth saying so plainly. Note also that despite being sold alongside peptides, 5-Amino-1MQ is a small molecule, not a peptide at all.

The human evidence, which does not exist

A targeted PubMed search returns no human clinical trial of 5-Amino-1MQ. Not a phase 1 safety study. Not a pharmacokinetic study. Nothing. Zero human efficacy data and zero human safety data.

Sit with what that rules out. Nobody knows its side-effect profile, because nobody has measured one. Nobody knows what dose does anything in a human, or what dose causes harm. Nobody knows how it interacts with medicines people actually take, how it is cleared, or what happens over months rather than days. Every one of those questions has an answer for an approved drug and no answer here.

The only NNMT inhibitor in a registered human trial is AstraZeneca's AZD4248, a different molecule, at phase 1 safety stage. A pharmaceutical company taking the target seriously enough to run a phase 1 is evidence that NNMT inhibition is a legitimate research direction. It is not evidence about 5-Amino-1MQ, which has not entered that process.

No data is not good data A compound with no reported side effects because nobody has studied it reads, in marketing copy, exactly like a compound with no side effects. Those are opposite situations. An approved drug's long warning list exists because people looked.

Why mouse metabolic results so often fail in humans

Obesity pharmacology has a long record of targets that worked beautifully in rodents and did nothing in people. Mouse metabolism differs from human metabolism in energy expenditure per unit mass, thermoregulation and gut hormone biology, and laboratory mice are genetically uniform animals living in controlled conditions, which produces clean results that human populations never reproduce.

An 11-day rat study is also short. An obesity treatment has to work for years, and short-term weight change in a rodent is one of the weakest available predictors of long-term weight change in a person. That is precisely why the regulatory pathway requires trials running 48 to 104 weeks. The preclinical stage is where most candidates die, and a compound skipping the human stage entirely has not passed anything.

Purity, dose accuracy and mislabelling

Even a compound that worked would still have to be the compound in the vial. FDA has found compounded GLP-1 products containing salt forms not equivalent to the approved active ingredient, which is direct documented evidence that non-standard supply chains ship mislabelled actives. Its stated concerns for the peptides placed in Category 2 were immunogenicity risk, peptide-related impurities and insufficient safety data, and those apply with more force to unregulated supply than to a compounding pharmacy.

Concentration is the practical failure. A vial labelled with a quantity that has never been assayed makes any dose figure meaningless, because the amount actually administered is unknown. Trial results cannot be carried across to material of unknown content, however carefully someone reads the paper.

The legal position

Selling a substance labelled for research use is not the same as that substance being approved for human use, and the label does not create a legal route. The specific position varies by jurisdiction and is a question for a lawyer rather than a health site. A research-use-only label is a disclaimer, not a permission.

What to do with an interesting-sounding compound

Two questions settle most cases quickly. Has this been given to humans in a published trial, and if so, did it separate from placebo? If the answer to the first is no, everything being claimed is extrapolation from animals or from mechanism.

After that, check whether percentages carry a trial name, a dose and a duration, and whether a positive animal result is described in language that hides the species. If a compound genuinely looks promising, the way to encounter it is a registered trial: they recruit, the material is the actual drug, and somebody is monitoring you.

Not medical advice Educational content only, with no sourcing, purity-testing or dosing guidance. 5-Amino-1MQ has no legal human-use route and no human data of any kind as of 23 August 2026. Discuss weight-loss treatment with a licensed prescriber.

The evidence, one row per claim

Claim	Tier	Source
A targeted PubMed search returns no human clinical trial of 5-Amino-1MQ: zero human safety data and zero human efficacy data.	established	Evidence review (re-run the PubMed search at publish time to confirm)
The preclinical case is real: inhibiting NNMT in adipose tissue raised intracellular NAD+ and SAM, suppressed lipogenesis and reduced body weight and white-fat mass in diet-induced-obese mice; diet-induced obese rats given 5-Amino-1MQ showed about 6% body-weight reduction over 11 days.	emerging	Secondary guide summarising preclinical work
The only NNMT inhibitor in a registered human trial is AstraZeneca's AZD4248, a different molecule, at phase 1 safety stage.	emerging	Secondary (verify on clinicaltrials.gov)
5-Amino-1MQ is not FDA-approved and is sold as an unregulated research chemical.	established	Secondary evidence review
FDA's stated concerns for the peptide Category 2 list were immunogenicity risk, peptide-related impurities and insufficient safety data, which are the same quality concerns that apply to grey-market supply.	established	FDA
FDA has found compounded GLP-1 products containing salt forms not equivalent to the approved active ingredient, demonstrating that non-standard supply chains do produce mislabelled actives.	established	FDA

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 6 sourced claims below the fold, each with the document it came from.

Sources consulted: Evidence review, Secondary guide summarising preclinical work, Secondary, Secondary evidence review, FDA.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

Research-Chemical Peptides: 5-Amino-1MQ and the Grey Market